Sign up for free insights newsletter
WuXi AppTec Co Ltd H

WuXi AppTec Co Ltd H

2359Hong Kong Stock Exchange

Need professional-grade analysis? Visit stockanalysis.com

HK$113.60
+6.17%
End of day
Market Cap

$330.42B

P/E Ratio

18.38

Employees

39,414

Dividend Yield

1.22%

Price Chart

Risk-Adjusted Performance

Ratio1W1M3M6M1Y5YScore
Sortino-1.78-2.471.44-0.171.640.34
Calmar-20.02-5.262.15-0.251.85-1.05
Sharpe-1.24-2.250.92-0.121.140.15
Omega0.440.421.191.011.231.00
Martin-34.67-7.054.50-0.415.24-0.72
Ulcer1.6812.468.0611.8210.9710.19

WuXi AppTec Co Ltd H (2359) Price Performance

WuXi AppTec Co Ltd H (2359) trades on Hong Kong Stock Exchange in HKD. The company is classified in the Healthcare sector under the Diagnostics & Research industry. The stock currently trades at HKD113.60, up 6.17% from the previous close.

Over the past year, 2359 has traded between a low of HKD47.45 and a high of HKD127.50. The stock has gained 73.2% over this period. It is currently 10.9% below its 52-week high.

WuXi AppTec Co Ltd H has a market capitalization of $330.42B, with a price-to-earnings ratio of 18.38 and a dividend yield of 1.22%.

About WuXi AppTec Co Ltd H

WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions which support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides laboratory testing services, such as toxicology, DMPK, and bioanalytical services; clinical contract research organization services, including Phase I to Phase IV clinical development services, and bioequivalence for products including pharmaceuticals and biologics; and site management organization, patient recruitment, site start-up, and academic research organization. In addition, it offers services for biology; CDRMO platform for small molecules, oligonucleotides, and peptides; drug research and development testing; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.

Company Info

Exchange
Hong Kong Stock Exchange
Currency
HKD
Country
Hong Kong

Financial Metrics

Revenue (TTM)
$43.88B
EBITDA
$18.00B
Profit Margin
34.17%
EPS (TTM)
4.16
Book Value
27.87

Technical Indicators

52 Week High
HK$129.90
52 Week Low
HK$43.43
50 Day MA
HK$115.76
200 Day MA
HK$104.20
Beta
0.62

Valuation

Trailing P/E
18.38
Forward P/E
23.81
Price/Sales
7.53
Price/Book
4.03
Enterprise Value
$286.48B